Displaying 200 (all) recruiting clinical trials.
-
A dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with pembrolizumab and/or chemotherapy for treatment of patients with locally advanced or metastatic urothelial cancer (SGN22E-002)
The purpose of this study to find out how enfortumab vedotin, when given together with pembrolizumab, cisplatin, carboplatin, or gemcitabine, affects patients with metastatic urothelial ... -
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ... -
A Phase I/II study Evaluating the Dosing Safety Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer
You are being asked to take part in this study because you have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and you ... -
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma
The main purpose of this study is to test the safety, tolerability, and effectiveness of the study drug tocilizumab when given with the drugs ipilimumab ... -
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
While outcomes in SR B-ALL have improved significantly, this population still accounts for approximately half of the overall burden of relapse among children with ALL ... -
A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment ... -
Radiation Dermatitis: A phase 1 randomized double blinded placebo controlled study of the safety and efficacy of a caffeine-based antifibrosis cream in patients with breast cancer undergoing radiation therapy (ReDCoAT Study)
The purpose of the study is to evaluate whether a caffeine-based cream can reduce the rates of complications in patients with tissue expander based reconstruction ... -
A Phase 3 Randomized Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
This is a research study involving the drug pembrolizumab. The purpose of this study is to: o See if the study drug, pembrolizumab, in combination ... -
A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
The purpose of this study is to determine if the investigational drug, infigratinib, is an effective treatment for cholangiocarcinoma (bile duct cancer) compared with the ... -
A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
The purpose of this study is to test the safety and to define the appropriate dose of an investigational drug (CC-220) and an investigational combination ...